BICYCLE THERAPEUTICS PLC (BCYC)

Current Report Filed: 2026-04-30

Key Insights

Bicycle Therapeutics announced Q1 2026 financial results on April 30, 2026, indicating the company is actively reporting operational progress and financial performance to shareholders.
The filing is a routine earnings announcement (Item 2.02) with the press release furnished but not filed, meaning it does not have the liability protections of official SEC filings.
The company maintains its listing on NASDAQ under ticker BCYC with both ordinary shares and American Depositary Shares available for trading.

Quarterly Report Filed: 2026-04-30

Key Insights

The filing contains extensive stock compensation plan disclosures across multiple plans (2019, 2020, and 2024 Inducement Plan), indicating ongoing equity-based compensation as a significant expense component for the biotech company.
References to strategic reprioritization of clinical portfolio in Q1 2026 suggest material changes to development strategy, with associated R&D and G&A expense impacts that warrant careful monitoring.
Multiple collaboration agreements with major pharma partners (Novartis, Genentech, Bayer, Ionis) are documented with deferred revenue and material rights options, representing potential future revenue streams and validation of technology platform.
The company maintains operations across US and UK locations, with specific references to new office and laboratory space in Cambridge, UK, indicating geographic expansion and corresponding facility-related expenses.

Insider Trading Filed: 2026-04-06

Key Insights

Insider Michael Skynner, the Chief Scientific Officer, sold a total of 2,404 ordinary shares of Bicycle Therapeutics PLC on April 2 and April 6, 2026 at a weighted average price of $4.91 and $5.05 per share, respectively.
The shares sold were to cover statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs), which is a mandatory 'sell-to-cover' transaction and not a discretionary sale.
Following the reported transactions, Skynner still holds a direct beneficial ownership of 159,562 ordinary shares in the company.

Insider Trading Filed: 2026-04-06

Key Insights

The CEO, Kevin Lee, sold a total of 7,683 shares of Bicycle Therapeutics PLC (BCYC) on April 2nd and April 6th, 2026 at weighted average prices of $4.91 and $5.05 respectively.
The sales were made to cover statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs), and not discretionary sales.
After the reported transactions, the CEO still holds 611,313 ordinary shares of the company, indicating he maintains a significant equity stake.

Insider Trading Filed: 2026-04-06

Key Insights

Jennifer Scott Perry, the Chief Operating Officer of Bicycle Therapeutics PLC, made sales of the company's ordinary shares on April 2, 2026 and April 6, 2026, likely to cover statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs).
The sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025, indicating a pre-planned nature of the transactions.
The total number of shares sold was 1,408, representing a minor reduction in Perry's direct beneficial ownership from 92,834 shares to 92,464 shares.

Insider Trading Filed: 2026-04-06

Key Insights

The reporting person, Travis Thompson, sold 799 ordinary shares on April 2, 2026 and 102 ordinary shares on April 6, 2026, likely to cover statutory tax withholding obligations related to the vesting and settlement of his restricted stock units (RSUs).
The reported sales represent a small fraction (less than 1%) of the reporting person's total beneficial ownership of 65,364 ordinary shares, indicating the transactions were routine in nature.
The reporting person's role as the Chief Financial Officer suggests the share sales were not driven by negative sentiment towards the company's performance or prospects.

Insider Trading Filed: 2026-04-06

Key Insights

Reporting person Michael Charles Ferguson, the Chief Product and Supply Chain Officer of Bicycle Therapeutics PLC, sold 1,772 ordinary shares on April 2 and April 6, 2026 to cover statutory tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs).
The shares were sold at weighted average prices of $4.91 and $5.05, respectively, and the reporting person continues to beneficially own 96,136 ordinary shares.
The sale of shares to cover tax withholding obligations is a routine transaction and does not necessarily indicate a change in the reporting person's long-term outlook on the company.

Current Report Filed: 2026-03-17

Key Insights

Bicycle Therapeutics announced the appointment of Jennifer Perry, Pharm.D. as the new Chief Operating Officer, effective March 17, 2026, succeeding Alistair Milnes who will take on the role of Chief Corporate Development Officer.
The company reported its financial results for the fiscal quarter and full year ended December 31, 2025, which will be of interest to investors.
Dr. Perry has over 20 years of experience in the biotech and pharmaceutical industries, including 15 years in oncology, which could provide valuable leadership for the company's development and commercialization efforts.

Annual Report Filed: 2026-03-17

Key Insights

The company's revenue and earnings growth appear to be slowing, which could be a concern for investors.
The company has undertaken cost reduction initiatives, including consolidating discovery research activities, which may impact future R&D and operational capabilities.
The company's collaboration agreements with Novartis, Ionis, and others continue to be an important part of its business strategy, but the expiration or amendment of these agreements could have a significant impact on the company's financial performance.

Insider Trading Filed: 2026-02-04

Key Insights

Travis Thompson, the Chief Financial Officer of Bicycle Therapeutics PLC, has been granted a stock option to acquire 58,000 ordinary shares of the company at an exercise price of $6.49 per share.
The option will vest over a four-year period, with the first 25% vesting on February 3, 2027 and the remaining shares vesting in 36 equal monthly installments thereafter.
This option grant represents a vote of confidence in Thompson's leadership and aligns his interests with those of the company and its shareholders.

Current Report Filed: 2026-01-12

Key Insights

Bicycle Therapeutics plc issued a press release on January 12, 2026, outlining its recent accomplishments and strategic priorities for the year.
The company's securities, including ordinary shares and American Depositary Shares, are listed on The Nasdaq Stock Market LLC.
Bicycle Therapeutics identifies itself as an emerging growth company, which could provide certain regulatory and financial reporting advantages.

Insider Trading Filed: 2026-01-06

Key Insights

Baker Bros. Advisors LP, a 10% owner of Bicycle Therapeutics PLC (BCYC), has acquired 38,000 new share options and 38,000 additional American Depositary Shares (ADSs) through the company's 2020 Equity Incentive Plan.
The new share options and ADS acquisitions suggest continued long-term confidence and commitment from a major institutional investor in the company.
The vesting schedule of the restricted share units (RSUs) granted to Felix J. Baker, a managing member of Baker Bros. Advisors, aligns his interests with long-term shareholder value creation.

Insider Trading Filed: 2026-01-06

Key Insights

The reporting person, Robert Charles Swanton, was granted 3,726 restricted share units (RSUs) that will vest over the next year.
Swanton was also granted 7,453 stock options that will vest over the next year, indicating an alignment of interests with shareholders.
The insider acquisition of shares and options suggests a positive outlook on the company's future prospects.

Insider Trading Filed: 2026-01-06

Key Insights

The reporting person, Jose-Carlos Gutierrez-Ramos, acquired 9,500 ordinary shares of Bicycle Therapeutics PLC through a restricted share unit (RSU) award, indicating an increase in his beneficial ownership of the company's stock.
The reporting person was also granted 19,000 stock options with an exercise price of $7.08, which will vest in four equal installments over the next year.
The insider transactions suggest a positive sentiment towards the company's prospects, as the reporting person, who is a director, is increasing his ownership stake.

Insider Trading Filed: 2026-01-06

Key Insights

The reporting person, Janice Bourque, was granted 9,500 restricted share units (RSUs) and 19,000 stock options on January 2, 2026. This indicates that the company is incentivizing its director through equity-based compensation.
The RSUs and stock options will vest in four equal installments over the course of 2026, suggesting the company is providing long-term incentives to the director.
The exercise price of the stock options is $7.08, which is the current market price of the company's ordinary shares, indicating the options are granted at-the-money.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information